The past decade has seen a notable change in the pattern of metastasis in men with metastatic castration-resistant prostate cancer (mCRPC), according to data from 270 phase II and 20 phase III therapeutic studies, involving 19,110 men with mCRPC. From 1990 to 2012, rates of nonosseous metastasis and lymph node metastasis increased by 1.6% and 1.4% per year, respectively, whereas the rate of osseous metastasis decreased by 0.5% per year and the rate of liver and lung metastasis remained relatively stable.